{"id":266,"date":"2026-09-05T12:55:47","date_gmt":"2026-09-05T07:25:47","guid":{"rendered":"https:\/\/tadalafil-seller.com\/blog\/?p=266"},"modified":"2026-09-05T12:55:47","modified_gmt":"2026-09-05T07:25:47","slug":"tadalafil-api-suppliers-with-dmf-support","status":"publish","type":"post","link":"https:\/\/tadalafil-seller.com\/blog\/tadalafil-api-suppliers-with-dmf-support\/","title":{"rendered":"Tadalafil API Suppliers With DMF Support: Buyer Guide"},"content":{"rendered":"

<\/p>\n

\n

Direct answer<\/p>\n

A tadalafil API supplier with DMF support holds a Type II Drug Master File with the FDA and will issue a Letter of Authorization allowing your application to reference it. DMF support is a contractual commitment, not just a document. Confirm the LOA scope, timeline and maintenance obligations before placing an order.<\/p>\n<\/div>\n\n\n\n\n
\n
\n

21 CFR 314.420<\/p>\n

The regulation governing US drug master files<\/p>\n<\/div>\n<\/td>\n

\n
\n

Type II<\/p>\n

The category covering a drug substance<\/p>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n

One per filing<\/p>\n

Each referencing application needs its own LOA<\/p>\n<\/div>\n<\/td>\n

\n
\n

Annual<\/p>\n

Report cycle the holder must keep up<\/p>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

“DMF support available” appears on almost every tadalafil API listing you will encounter. It is one of the least examined phrases in generic sourcing, because it sounds like a property of the supplier when it is really a description of something the supplier has agreed to do for you, at some point, on terms nobody has written down yet.<\/p>\n

The gap between “we have a DMF” and “your ANDA can reference our DMF, on this timeline, and we will keep it current for the life of your product” is where filing delays are manufactured. This guide covers what to ask for, what to contract for, and what happens when support quietly stops.<\/p>\n

What does DMF support actually mean?<\/h2>\n

A Drug Master File lets a manufacturer give FDA confidential detail about its process without disclosing that detail to its customer. Your application incorporates the file by reference, which the regulation permits only if the holder authorises it in writing. [Source: 21 CFR 314.420(b)]<\/p>\n

That written authorisation is the Letter of Authorization: a statement by the holder or its designated agent permitting FDA to refer to information in the DMF in support of another person’s submission. [Source: FDA, Guideline for Drug Master Files]<\/p>\n

So “DMF support” decomposes into three separate things, and a supplier can have the first without ever delivering the second or third:<\/p>\n

    \n
  • A file exists.<\/strong> A Type II DMF has been submitted and has a number.<\/li>\n
  • The holder will authorise you.<\/strong> They will issue an LOA naming you, your application, and the scope of reference.<\/li>\n
  • The holder will maintain it.<\/strong> Amendments for process, site or ownership changes, and annual reports, for as long as your product is on the market.<\/li>\n<\/ul>\n

    Only the first is visible from a supplier listing. The other two are commercial commitments, and they are the ones that determine whether your filing survives. For the verification side of the first item, see our guide to USDMF tadalafil API manufacturers.<\/p>\n

    \"What<\/p>\n

    Which DMF type applies to tadalafil?<\/h2>\n

    Type II. It covers the drug substance, drug substance intermediates and materials used in their preparation, or the drug product. If a supplier offers a different type as support for your tadalafil drug substance, something is misaligned. [Source: 21 CFR 314.420(a)]<\/p>\n

    The remaining live categories are Type III for packaging materials, Type IV for excipients, colorants, flavours and essences, and Type V for FDA-accepted reference information. Type I, which covered manufacturing sites and personnel, was discontinued in 2000 and is no longer accepted for new submissions.<\/p>\n

    One structural point that catches buyers out: a foreign DMF holder should designate a US Agent physically located in the United States to receive FDA correspondence on its behalf. Missed FDA correspondence is a common route to deficiencies that surface as problems in your application, not theirs. [Source: 21 CFR 314.420(a)(3)]<\/p>\n

    How the Letter of Authorization workflow runs<\/h2>\n\n\n\n\n\n\n\n
    \n
    01<\/div>\n<\/td>\n
    		\n

    Request the LOA in writing, with your details<\/p>\n

    The holder needs your legal entity name, the application you are filing, and the scope of reference. Provide these early. Vague requests produce vague letters.<\/p>\n<\/td>\n<\/tr>\n

    \n
    02<\/div>\n<\/td>\n
    		\n

    Check the letter identifies the file precisely<\/p>\n

    The regulation requires each incorporation by reference to describe the incorporated material by name, reference number, volume and page number of the drug master file. A letter that gestures at “our DMF” without that specificity creates work later. [Source: 21 CFR 314.420(b)]<\/p>\n<\/td>\n<\/tr>\n

    \n
    03<\/div>\n<\/td>\n
    		\n

    Confirm the holder sends its copy to FDA and to you<\/p>\n

    FDA’s guideline describes both the letter to the agency and a copy to the applicant. You need your copy for your own dossier and audit trail.<\/p>\n<\/td>\n<\/tr>\n

    \n
    04<\/div>\n<\/td>\n
    		\n

    Settle who pays the GDUFA fee, and when<\/p>\n

    For a Type II API DMF referenced by a generic drug submission, a one-time user fee is owed by the DMF owner, triggered by the first reference or by a request for the initial completeness assessment. Establish in advance that it is paid, because an unpaid fee has consequences for your application, not just theirs.<\/p>\n<\/td>\n<\/tr>\n

    \n
    05<\/div>\n<\/td>\n
    		\n

    Plan for a new LOA per application<\/p>\n

    An LOA is specific to the applicant and the submission it supports. A second product, a second entity, or a separate supplement generally means going back to the holder. Build that round trip into your timeline rather than discovering it at filing.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    What to secure in the supply and quality agreement<\/h2>\n

    This is the section that separates a sourcing decision from a procurement transaction. Everything below is a commercial term, not a regulatory one, which means it exists only if you negotiate it.<\/p>\n

    \n
      \n
    • LOA commitment and timeline.<\/strong> An obligation to issue an LOA on request, within a defined number of business days, for named applications.<\/li>\n
    • Fee allocation.<\/strong> Who pays the GDUFA DMF fee, and what happens if it goes unpaid.<\/li>\n
    • Maintenance obligation.<\/strong> A commitment to keep the DMF active, file annual reports, and submit amendments for relevant changes.<\/li>\n
    • Change notification.<\/strong> Advance written notice of any change to site, route, specification, ownership or US Agent, with a defined notice period before implementation.<\/li>\n
    • Site and route lock.<\/strong> Confirmation that supplied material comes from the site and route the DMF describes, with notice if that changes.<\/li>\n
    • Status transparency.<\/strong> A right to be told promptly if the file receives a deficiency, is placed in inactive status, or is closed.<\/li>\n
    • Continuity on exit.<\/strong> What happens to your reference rights if the holder is acquired, discontinues the product, or terminates supply.<\/li>\n
    • Audit rights.<\/strong> The right to audit the manufacturing site, on reasonable notice.<\/li>\n<\/ul>\n<\/div>\n

      What happens when DMF support lapses<\/h2>\n

      FDA ordinarily does not independently review drug master files or approve or disapprove them. It reviews the information in the context of an application. [Source: 21 CFR 314.420(a)]<\/p>\n

      \n

      The asymmetry to understand<\/p>\n

      That means the DMF’s problems surface as your problems. A deficient, unmaintained or inactive file becomes visible through information requests, review delays and, in the worst case, a complete response on your application. The holder experiences an administrative inconvenience. You experience a missed launch window. Nothing in the regulatory framework rebalances that, which is why it has to be handled contractually.<\/p>\n<\/div>\n

      A practical consequence: build a periodic re-check of your API supplier’s DMF status into your regulatory calendar, not just into initial qualification. FDA’s DMF list is refreshed quarterly, which is a reasonable cadence to match.<\/p>\n

      DMF support across markets: the global equivalents<\/h2>\n

      If your tadalafil product is going to more than one region, “DMF support” means a different document in each. A supplier strong in one column may have nothing in another.<\/p>\n\n\n\n\n\n\n\n\n
      Market<\/th>\nDocument<\/th>\nAccess mechanism<\/th>\n<\/tr>\n<\/thead>\n
      United States<\/td>\nType II DMF<\/td>\nLetter of Authorization to FDA<\/td>\n<\/tr>\n
      Europe<\/td>\nCEP or ASMF<\/td>\nReference the CEP, or an ASMF letter of access<\/td>\n<\/tr>\n
      Japan<\/td>\nJDMF (Master File)<\/td>\nRegistration number plus holder consent<\/td>\n<\/tr>\n
      South Korea<\/td>\nKDMF<\/td>\nRegistration plus holder consent<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

      Requirements and procedures differ by authority and change over time. Confirm current requirements with the relevant regulator or your regulatory affairs advisor before planning a multi-market filing. See also our guide to CEP-certified tadalafil API suppliers.<\/p>\n

      \"DMF<\/p>\n

      Red flags in DMF support claims<\/h2>\n
      \n

      Escalate to QA or RA before proceeding<\/p>\n

        \n
      • “DMF support available” with no DMF number offered when asked directly<\/li>\n
      • An LOA promised only after payment, or contingent on a minimum order quantity<\/li>\n
      • A blanket or undated letter that names no applicant and no application<\/li>\n
      • No named US Agent for a foreign holder<\/li>\n
      • No answer on when the file was last amended or when the last annual report was filed<\/li>\n
      • Reluctance to accept a change-notification clause in the quality agreement<\/li>\n
      • An intermediary offering support for a file it does not hold, without documenting its relationship to the holder<\/li>\n
      • Any claim that the DMF means the API is “FDA approved”. FDA does not approve DMFs<\/li>\n<\/ul>\n<\/div>\n

        Clinical context: what the API becomes<\/h2>\n

        Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor. In the United States it is approved in finished dosage form for erectile dysfunction, the signs and symptoms of benign prostatic hyperplasia, and pulmonary arterial hypertension, marketed as Cialis and Adcirca and as generics. [Source: FDA Prescribing Information, Cialis and Adcirca]<\/p>\n

        Uses outside those approved indications are off-label and fall outside the labelling that supports them. The finished product’s profile is what drives the impurity, uniformity and stability expectations placed on your drug substance, which is the practical reason an API buyer should know it.<\/p>\n\n\n\n\n\n\n\n
        Approved US indication<\/th>\nDosing pattern per labelling<\/th>\nCommon strengths<\/th>\n<\/tr>\n<\/thead>\n
        Erectile dysfunction<\/td>\nAs-needed or once daily<\/td>\n2.5, 5, 10, 20 mg<\/td>\n<\/tr>\n
        Benign prostatic hyperplasia<\/td>\nOnce daily<\/td>\n5 mg<\/td>\n<\/tr>\n
        Pulmonary arterial hypertension<\/td>\nOnce daily<\/td>\n20 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

        Provided for orientation only, drawn from approved labelling. Dosing decisions belong to a prescribing clinician. [Source: FDA Prescribing Information, Cialis and Adcirca]<\/p>\n

        \n

        Who should not take tadalafil<\/p>\n

          \n
        • Anyone using organic nitrates in any form. Clinical studies indicate tadalafil augments the hypotensive effects of nitrates, and co-administration is contraindicated. [Source: EMA Summary of Product Characteristics, Cialis]<\/li>\n
        • Anyone with known hypersensitivity to tadalafil or any component of the formulation.<\/li>\n
        • Caution applies with alpha-blockers and other antihypertensives because of additive blood-pressure effects, and in patients for whom sexual activity is inadvisable on cardiovascular grounds.<\/li>\n
        • Caution applies in patients predisposed to priapism, including those with sickle cell anaemia, multiple myeloma or leukaemia. [Source: Health Canada Product Monograph, CIALIS]<\/li>\n<\/ul>\n

          Labelled warnings include prolonged erection and priapism, sudden decrease or loss of vision associated with non-arteritic anterior ischaemic optic neuropathy, and sudden decrease or loss of hearing. Commonly reported adverse reactions include headache, dyspepsia, back pain, myalgia, flushing and nasal congestion. The product carries no boxed warning in the US. [Source: FDA Prescribing Information, Cialis]<\/p>\n<\/div>\n

          When to see a doctor<\/h3>\n

          Anyone taking tadalafil who experiences an erection lasting more than four hours, sudden vision or hearing changes, chest pain, fainting, or signs of an allergic reaction should seek medical attention promptly. Tadalafil is a prescription medicine and should be taken only under the supervision of a licensed clinician.<\/p>\n

          \n

          A note on unapproved products.<\/strong> Tadalafil sold without a prescription, through unlicensed online channels, or marketed as a “natural” or herbal alternative sits outside the regulated supply chain. Products sold as botanical or dietary supplements have repeatedly been found to contain undeclared PDE5 inhibitors, which creates a real interaction risk for anyone taking nitrates and offers no assurance of identity, strength or purity. This site supplies pharmaceutical-grade API to qualified business buyers only and does not sell to individuals or supply finished medicines to consumers.<\/p>\n<\/div>\n

          Frequently asked questions<\/h2>\n
          \nWhat does DMF support mean from an API supplier?<\/summary>\n

          It should mean three things: the supplier holds a Type II Drug Master File, it will issue you a Letter of Authorization permitting FDA to reference that file in support of your submission, and it will keep the file maintained. Only the first is visible from a listing. The other two are commercial commitments you need in writing.<\/p>\n<\/details>\n

          \nWho issues the Letter of Authorization?<\/summary>\n

          The DMF holder, or its designated agent or representative. If the company quoting you is not the holder, ask it to document its relationship to the holder and confirm who will actually sign the letter.<\/p>\n<\/details>\n

          \nDoes each application need its own LOA?<\/summary>\n

          Plan on it. An authorisation is tied to the applicant and the submission it supports, and each incorporation by reference must identify the material by name, reference number, volume and page. Treat a second product or a second filing entity as requiring a fresh request.<\/p>\n<\/details>\n

          \nCan a supplier refuse to issue an LOA after I have ordered?<\/summary>\n

          Nothing in the regulatory framework obliges a DMF holder to authorise anyone. Authorisation is at the holder’s discretion, which is precisely why the obligation and its timeline belong in your supply agreement rather than in an email thread.<\/p>\n<\/details>\n

          \nSafety: why does the nitrate contraindication matter to an API buyer?<\/summary>\n

          Because it sets the stakes for everything upstream. Clinical studies indicate tadalafil augments the hypotensive effects of nitrates, and co-administration is contraindicated. That is why the molecule is prescription-only, why identity and strength control at the drug substance stage is not a paperwork exercise, and why the integrity of the documentation chain behind your API genuinely matters. [Source: EMA Summary of Product Characteristics, Cialis]<\/p>\n

          Sources<\/h2>\n
            \n
          1. 21 CFR 314.420, Drug master files.<\/li>\n
          2. US FDA. Guideline for Drug Master Files (DMF).<\/li>\n
          3. US FDA. Completeness Assessments for Type II API DMFs Under GDUFA, Guidance for Industry, October 2017.<\/li>\n
          4. Federal Food, Drug, and Cosmetic Act, section 744B.<\/li>\n
          5. US FDA. Prescribing Information, Cialis and Adcirca.<\/li>\n
          6. European Medicines Agency. Summary of Product Characteristics, Cialis.<\/li>\n
          7. Health Canada. Product Monograph, CIALIS.<\/li>\n<\/ol>\n
            \n

            This article is for informational purposes only and is not a substitute for professional medical advice. Consult your doctor before starting, stopping, or changing any medication. Regulatory and contractual information is provided for general guidance and does not constitute regulatory or legal advice. Verify requirements against current FDA sources and take your own legal advice before entering a supply agreement.<\/p>\n<\/div>\n

            B2B supply only. We do not sell prescription medicines to individuals.<\/p>\n<\/details>\n","protected":false},"excerpt":{"rendered":"

            Direct answer A tadalafil API supplier with DMF support holds a Type II Drug Master File with the FDA and will issue a Letter of Authorization allowing your application to reference it. DMF support is a contractual commitment, not just a document. Confirm the LOA scope, timeline and maintenance obligations before placing an order. 21 […]<\/p>\n","protected":false},"author":1,"featured_media":267,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"pb_authors":"[{\"role\":\"Written by\",\"name\":\"Dr Arnika Sharma\",\"credentials\":\"MBBS, MD (Medicine)\",\"linkedin\":\"https:\\\/\\\/www.linkedin.com\\\/in\\\/dr-arnika-sharma-31a183245\\\/\",\"bio\":\"Medical Science Liaison with a strong passion for advancing scientific exchange and improving patient outcomes through evidence-based communication. Experienced in building trusted relationships with healthcare professionals, key opinion leaders (KOLs), and cross-functional teams to support the responsible use of innovative therapies.\"}]","pb_last_updated":"","pb_uses_pdg":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-266","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-guide"],"_links":{"self":[{"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/posts\/266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/comments?post=266"}],"version-history":[{"count":2,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/posts\/266\/revisions"}],"predecessor-version":[{"id":271,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/posts\/266\/revisions\/271"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/media\/267"}],"wp:attachment":[{"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/media?parent=266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/categories?post=266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/tags?post=266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}